Literature DB >> 19693511

[Possibilities and limitations of telemedical home monitoring in ophthalmology].

C Jürgens1, R Grossjohann, F Tost.   

Abstract

For medical professionals, home monitoring represents an innovative health service for remote patient care: The patient may remain in his or her domestic environment and continue normal activities. The physician can also, through technical and organizational integration, provide medical attendance from his or her usual working environment. All in all, in the near future home monitoring can help provide sufficient health services while also enabling medical resources to be used more effectively. The patient may benefit from individually optimized treatment and active integration into medical care. The better we manage the technical, organizational, medical, legal, and economic challenges of telemedicine, the better we can minimize the limitations of telemedical home monitoring. Other existing subjective concerns will be eliminated only if telemedical concepts are adapted to the specific needs of affected patients and physicians.

Entities:  

Mesh:

Year:  2009        PMID: 19693511     DOI: 10.1007/s00347-009-1960-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  13 in total

Review 1.  Assessing telemedicine: a systematic review of the literature.

Authors:  R Roine; A Ohinmaa; D Hailey
Journal:  CMAJ       Date:  2001-09-18       Impact factor: 8.262

2.  [Home-monitoring in ophthalmology--prerequisites for an improvement in quality of life: conclusions from the management research study Teletonometry Mecklenburg-Vorpommern].

Authors:  C Jürgens; R Grossjohann; J Meiering; C Meinke; S Antal; F H Tost
Journal:  Klin Monbl Augenheilkd       Date:  2009-06-08       Impact factor: 0.700

3.  New frontiers in home telemonitoring. It's already here. Where are you?

Authors:  Colin Konschak; Bruce Flareau
Journal:  J Healthc Inf Manag       Date:  2008

Review 4.  The current state of telemonitoring: a comment on the literature.

Authors:  Stephane Meystre
Journal:  Telemed J E Health       Date:  2005-02       Impact factor: 3.536

Review 5.  [Progress in geriatric care through telemedicine].

Authors:  C Jürgens; F Tost
Journal:  Ophthalmologe       Date:  2006-09       Impact factor: 1.059

Review 6.  Systematic review of home telemonitoring for chronic diseases: the evidence base.

Authors:  Guy Paré; Mirou Jaana; Claude Sicotte
Journal:  J Am Med Inform Assoc       Date:  2007-02-28       Impact factor: 4.497

Review 7.  Systematic review of evidence for the benefits of telemedicine.

Authors:  David Hailey; Risto Roine; Arto Ohinmaa
Journal:  J Telemed Telecare       Date:  2002       Impact factor: 6.184

8.  [Fluctuation of intraocular pressure in 24-hour telemonitoring compared to tonometry during normal office hours].

Authors:  C Jürgens; S Antal; K Henrici; R Grossjohann; F H Tost
Journal:  Klin Monbl Augenheilkd       Date:  2009-01-27       Impact factor: 0.700

9.  [Diurnal variation of ocular pressure in open-angle glaucoma with telemonitoring].

Authors:  S Antal; C Jürgens; R Grossjohann; F H Tost
Journal:  Klin Monbl Augenheilkd       Date:  2009-03-17       Impact factor: 0.700

10.  [2 years self-tonometry. Acceptance and results].

Authors:  C Deutsch; J Draeger; S Groenhoff
Journal:  Ophthalmologe       Date:  1992-12       Impact factor: 1.059

View more
  3 in total

1.  [Fundus screening by medical technicians].

Authors:  F Schütt; T Bruckner; K Schäfer; D Lehnhoff; G Rudofsky; C Kasperk; P Nawroth; G U Auffarth
Journal:  Ophthalmologe       Date:  2013-02       Impact factor: 1.059

2.  [Health economical aspects of telemedical glaucoma monitoring].

Authors:  T Swierk; C Jürgens; R Grossjohann; S Flessa; F Tost
Journal:  Ophthalmologe       Date:  2011-04       Impact factor: 1.059

3.  [Ease of handling of first and second generation rebound tonometers].

Authors:  N Mihailovic; J Termühlen; M Alnawaiseh; N Eter; T S Dietlein; A Rosentreter
Journal:  Ophthalmologe       Date:  2016-04       Impact factor: 1.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.